Form 4: Adicet Bio, Inc. Executive Aftab Blake Reports Stock Option Grant

Chief Scientific Officer Aftab Blake reports the acquisition of stock options in Adicet Bio, Inc.

Summary

• On June 5, 2024, Aftab Blake, Chief Scientific Officer of Adicet Bio, Inc., reported the acquisition of stock options.
• The stock option grants the right to buy 336,911 shares of common stock at an exercise price of $2.53.
• The options vest in 48 equal monthly installments starting January 26, 2024, contingent upon continued service with the company, and expire on January 25, 2034.
• Following the transaction, Blake directly owns 336,911 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, incentivizing management and aligning interests with shareholders.

Positives

• The granting of stock options to the Chief Scientific Officer aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies, similar to companies like Amgen, Gilead, and Biogen.
• The vesting schedule of 48 months is typical for such grants, aligning with industry norms for long-term incentives.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the Chief Scientific Officer to drive company growth and innovation.
• Employees may view the grant as a positive sign of the company's commitment to its leadership team.

Key Dates